Literature DB >> 9028553

Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group.

K Takenaka1, H Gondo, K Tanimoto, K Nagafuji, T Fujisaki, S Mizuno, T Miyamoto, T Okamura, S Hayashi, T Eto, K Osaki, K Yamasaki, T Shibuya, N Harada, T Teshima, E Matsuishi, T Minematsu, Y Minamishima, M Harada, Y Niho.   

Abstract

Cytomegalovirus (CMV) infection and CMV-associated disease were monitored using the CMV antigenemia assay in 72 patients who received allogeneic bone marrow transplantation (BMT), and their incidences were compared between related and unrelated donor transplant patients. The incidence of CMV infection after BMT was significantly higher in patients who received transplants from HLA-matched unrelated donors than from HLA-matched sibling donors (87% vs 53%, P < 0.05). CMV-associated disease developed in 73% of unrelated and in 14% of sibling donor transplant patients (P < 0.01). The peak levels of CMV antigenemia were significantly higher in unrelated donors than in sibling donor transplant patients (16 vs 1 CMV antigen-positive cells per 50000 WBCs, P < 0.01). The median number of CMV antigen-positive cells on first detection was also significantly higher in unrelated donor transplant patients (15 vs 1, P < 0.01). The detection of CMV antigen-positive cells preceded the development of CMV-associated disease in 18% of unrelated donor transplant patients, suggesting a lower predictive value of CMV antigenemia for subsequent CMV-associated disease in unrelated donor BMT. Careful monitoring and further studies are needed for the early diagnosis and prevention of CMV-associated disease in unrelated donor BMT.

Entities:  

Mesh:

Year:  1997        PMID: 9028553     DOI: 10.1038/sj.bmt.1700637

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  12 in total

1.  Construction and Evaluation of Cytomegalovirus DNA Quantification System with Real-Time Detection Polymerase Chain Reaction.

Authors:  Yuki Hatayama; Yuki Hashimoto; Ayako Hara; Toru Motokura
Journal:  Yonago Acta Med       Date:  2016-09-12       Impact factor: 1.641

2.  Dextramer reagents are effective tools for quantifying CMV antigen-specific T cells from peripheral blood samples.

Authors:  Joseph D Tario; George L Chen; Theresa E Hahn; Dalin Pan; Rosemary L Furlage; Yali Zhang; Liselotte Brix; Charlotte Halgreen; Kivin Jacobsen; Philip L McCarthy; Paul K Wallace
Journal:  Cytometry B Clin Cytom       Date:  2014-10-23       Impact factor: 3.058

3.  Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study.

Authors:  David Beauvais; Elodie Drumez; Didier Blaise; Régis Peffault de Latour; Edouard Forcade; Patrice Ceballos; Anne Uyttebroeck; Hélène Labussière; Stéphanie Nguyen; Jean-Henri Bourhis; Patrice Chevallier; Anne Thiebaut; Xavier Poiré; Sébastien Maury; Eric Deconinck; Thomas Cluzeau; Eolia Brissot; Anne Huynh; Marie-Thérèse Rubio; Alain Duhamel; Ibrahim Yakoub-Agha
Journal:  Bone Marrow Transplant       Date:  2020-12-18       Impact factor: 5.483

4.  Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Katsuto Takenaka; Koji Nagafuji; Ken Takase; Tomohiko Kamimura; Yasuo Mori; Yoshikiyo Ito; Yukiko Nishi; Hideho Henzan; Koji Kato; Naoki Harada; Tetsuya Eto; Toshihiro Miyamoto; Takanori Teshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2012-05-01       Impact factor: 2.490

5.  Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.

Authors:  Fumiaki Jinnouchi; Yasuo Mori; Goichi Yoshimoto; Takuji Yamauchi; Takuya Nunomura; Ayano Yurino; Masayasu Hayashi; Junichiro Yuda; Takahiro Shima; Jun Odawara; Shuichiro Takashima; Kenjiro Kamezaki; Koji Kato; Toshihiro Miyamoto; Koichi Akashi; Katsuto Takenaka
Journal:  Int J Hematol       Date:  2021-10-15       Impact factor: 2.490

6.  Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Katsuto Takenaka; Tetsuya Eto; Koji Nagafuji; Kenjiro Kamezaki; Yayoi Matsuo; Goichi Yoshimoto; Naoki Harada; Maki Yoshida; Hideho Henzan; Ken Takase; Toshihiro Miyamoto; Koichi Akashi; Mine Harada; Takanori Teshima
Journal:  Int J Hematol       Date:  2009-01-17       Impact factor: 2.490

7.  Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis.

Authors:  Francisco M Marty; Julie Bryar; Sarah K Browne; Talya Schwarzberg; Vincent T Ho; Ingrid V Bassett; John Koreth; Edwin P Alyea; Robert J Soiffer; Corey S Cutler; Joseph H Antin; Lindsey R Baden
Journal:  Blood       Date:  2007-03-28       Impact factor: 22.113

8.  Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation.

Authors:  Satoshi Kaito; Yujiro Nakajima; Konan Hara; Takashi Toya; Tetsuya Nishida; Naoyuki Uchida; Junichi Mukae; Takahiro Fukuda; Yukiyasu Ozawa; Masatsugu Tanaka; Kazuhiro Ikegame; Yuta Katayama; Takuro Kuriyama; Junya Kanda; Yoshiko Atsuta; Masao Ogata; Ayumi Taguchi; Kazuteru Ohashi
Journal:  Blood Adv       Date:  2020-03-24

Review 9.  Cytomegalovirus pneumonia in hematopoietic stem cell recipients.

Authors:  Giovanna Travi; Steven A Pergam
Journal:  J Intensive Care Med       Date:  2013-02-06       Impact factor: 3.510

10.  Donor killer immunoglobulin-like receptor genes and reactivation of cytomegalovirus after HLA-matched hematopoietic stem-cell transplantation: HLA-C allotype is an essential cofactor.

Authors:  Carolyn E Behrendt; Ryotaro Nakamura; Stephen J Forman; John A Zaia
Journal:  Front Immunol       Date:  2013-02-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.